title: Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
abstract: SAR405838 is a potent and specific MDM2 inhibitor currently being evaluated in Phase I clinical trials for the treatment of human cancer. Using the SJSA-1 osteosarcoma cell line which harbors an amplified MDM2 gene and wild-type p53, we have investigated the acquired resistance mechanisms both in vitro and in vivo to SAR405838. Treatment of SJSA-1 cells with SAR405838 in vitro leads to dose-dependent cell growth inhibition, cell cycle arrest and robust apoptosis. However, prolonged treatment of SJSA-1 cells in vitro with SAR405838 results in profound acquired resistance to the drug. Analysis of in vitro-derived resistant cell lines showed that p53 is mutated in the DNA binding domain and can no longer be activated by SAR405838. Treatment of the parental SJSA-1 xenograft tumors with SAR405838 in mice yields rapid tumor regression but the tumors eventually regrow. Culturing the regrown tumors established a number of sublines, which showed only modest (3-5 times) loss of sensitivity to SAR405838 in vitro. Sequencing of the p53 showed that it retains its wild-type status in these in vivo sublines, with the exception of one subline, which harbors a single heterozygous C176F p53 mutation. Using xenograft models of two in vivo derived sublines, which has either wild-type p53 or p53 containing a single heterozygous C176F mutation, we showed that while SAR405838 effectively achieves partial tumor regression in these models, it no longer induces complete tumor regression and tumors resume growth once the treatment is stopped. Harvesting and culturing tumors obtained from a prolonged treatment with SAR405838 in mice established additional in vivo sublines, which all contain a single heterozygous C176F mutation with no additional p53 mutation detected. Interestingly, SAR405838 can still effectively activate p53 in all sublines containing a single heterozygous C176F mutation, with a moderately reduced potency as compared to that in the parental cell line. Consistently, SAR405838 is 3-5 times less effective in all the in vivo derived sublines containing a single heterozygous C176F p53 mutation than in the SJSA-1 parental cell line in assays of cell growth and apoptosis. Computational modeling suggested that a p53 tetramer containing two wild-type p53 molecules and two C176F mutated molecules can maintain the structural stability and interactions with DNA by formation of additional hydrophobic and cation-π interactions which compensate for the loss of sulphur-zinc coordination. Our data thus show that SJSA-1 tumor cells acquire very different levels of resistance in vitro and in vivo to the MDM2 inhibitor SAR405838. Our present study may have a significant implication for the investigation of resistant mechanisms for other classes of anticancer drugs.
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America; Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, United States of America.
authors.forename: C Gianna
authors.initials: CG
authors.lastname: Hoffman-Luca
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
authors.forename: Chao-Yie
authors.initials: CY
authors.lastname: Yang
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Lu
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America; Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, United States of America.
authors.forename: Daniel
authors.initials: D
authors.lastname: Ziazadeh
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
authors.forename: Donna
authors.initials: D
authors.lastname: McEachern
authors.affiliation: Sanofi Oncology, Vitry-sue-Seine, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Debussche
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America; Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, United States of America; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America; Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America.
authors.forename: Shaomeng
authors.initials: S
authors.lastname: Wang
mesh_terms: D019943:Amino Acid Substitution; D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D051379:Mice; D016513:Mice, SCID; D020125:Mutation, Missense; D012516:Osteosarcoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D013141:Spiro Compounds / Q000494:pharmacology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D007211:Indoles; D013141:Spiro Compounds; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C000593797:SAR405838; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2